May 15, 2024New England Journal of Medicine

Perioperative Nivolumab in Resectable Lung Cancer

View Full Paper

Ask AI

Bookmark

Authors

TCTina CasconeThe University of Texas MD Anderson Cancer Center MAMark M. AwadMemorial Sloan Kettering Cancer Center JSJonathan SpicerMcGill University Health Centre

Discussion

Member takes

Implication

Clinical evaluation reveals improved outcomes with perioperative nivolumab in resectable non-small-cell lung cancer, suggesting added benefits from adjuvant phases.

Key Points

Perioperative treatment with nivolumab may enhance clinical outcomes in patients with resectable non-small-cell lung cancer beyond standard neoadjuvant chemotherapy protocols.
Standard treatment utilizing neoadjuvant nivolumab combined with chemotherapy significantly improves disease outcomes before surgical resection is performed.
These therapeutic findings highlight the promise of adding adjuvant therapy following surgery to further consolidate survival outcomes in resectable non-small-cell lung cancer.

Cite This Study

Cascone et al. (2024) studied this question.

synapsesocial.com/papers/68e69d64b6db643587623078 https://doi.org/10.1056/nejmoa2311926

View Full Paper

Ask AI

Bookmark

Implication

Clinical evaluation reveals improved outcomes with perioperative nivolumab in resectable non-small-cell lung cancer, suggesting added benefits from adjuvant phases.

Perioperative Nivolumab in Resectable Lung Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Perioperative Nivolumab in Resectable Lung Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider